# Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01059799` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01059799](<https://clinicaltrials.gov/study/NCT01059799>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01059799

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.

## Technical summary

Registry record NCT01059799. Randomized; no masking; primary purpose treatment. Start 2010-02-01 (actual); primary completion 2010-12-16 (actual). Results posted on 2015-11-13.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 435 participants (enrolled count; ClinicalTrials.gov record NCT01059799, source copy `cardio:ctgov-nct01059799-2017-03-30`, retrieved 2026-10-26)
- Started: 2010-02-01 (actual) (ClinicalTrials.gov record NCT01059799, source copy `cardio:ctgov-nct01059799-2017-03-30`, retrieved 2026-10-26)
- Primary completion: 2010-12-16 (actual) (ClinicalTrials.gov record NCT01059799, source copy `cardio:ctgov-nct01059799-2017-03-30`, retrieved 2026-10-26)
- Completion: 2010-12-16 (actual) (ClinicalTrials.gov record NCT01059799, source copy `cardio:ctgov-nct01059799-2017-03-30`, retrieved 2026-10-26)
- Results first posted: 2015-11-13 (ClinicalTrials.gov record NCT01059799, source copy `cardio:ctgov-nct01059799-2017-03-30`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China; Japan; Malaysia; South Korea; Taiwan; Thailand (ClinicalTrials.gov record NCT01059799, source copy `cardio:ctgov-nct01059799-2017-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01059799-2017-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
- Acronym: BEGIN™
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec
- Intervention (Drug): insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 51fff53ae5cd533fe0f9fce07518844f4359178d918909bb96d631a4be39c2d9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
